The Q3 results modestly exceeded the company's own outlook, but the stock is now driven by the pending EQT take-private at $46.50/share, not quarterly operating performance. Monitor regulatory approvals and shareholder tender for deal completion timing, expected mid-2027.
Price Chart
Executive Summary
QIAGEN reported Q3 2026 net sales of $548M (+3% YoY, +3% CER) and adjusted diluted EPS of $0.65 ($0.65 CER), exceeding the outlook for ~1-2% CER growth and at least $0.62 CER. The company suspended its 2026 guidance due to the pending all-cash takeover by EQT Private Equity at $46.50 per share, with closing expected in mid-2027. GAAP diluted EPS declined 15% to $0.51 due to higher restructuring and acquisition-related charges.
Key Financial Metrics
Key Facts
- Q3 2026 net sales $548M, +3% YoY and +3% CER, above the outlook for ~1-2% CER growth
- Adjusted diluted EPS $0.65 ($0.65 CER), above the outlook for at least $0.62 CER
- GAAP diluted EPS $0.51, down 15% from $0.60 in Q3 2025
- Adjusted operating income margin 30.4%, up 80 bps from 29.6%
- Operating cash flow $447M for first nine months of 2026 vs $466M in prior-year period
- Free cash flow $319M for nine months vs $336M in prior-year period
- Suspended 2026 outlook due to pending EQT Private Equity acquisition at $46.50 per share
- Leverage ratio increased to 1.0x from 0.7x at year-end 2025 after $500M synthetic share repurchase and $72M dividend payment
- Parse Biosciences on track to exceed ~$40M sales target for 2026
- QIAstat-Dx sales grew 11% CER; QuantiFERON sales flat at $136M
Financial Impact
Q3 net sales $548M, adjusted diluted EPS $0.65; guidance suspended due to pending take-private
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Sample technologies | $187.0M | +10.0% |
| Diagnostic solutions | $209.0M | +1.0% |
| PCR Nucleic acid amplification | $71.0M | -5.0% |
| Genomics NGS | $66.0M | +9.0% |
| Other | $14.0M | -21.0% |
Risk Factors
- Pending EQT acquisition may not close as expected due to regulatory or shareholder hurdles
- GAAP net income declined 19% YoY due to higher restructuring and acquisition costs
- PCR nucleic acid amplification sales declined 5% CER, indicating weakness in a core product group
- Free cash flow declined 5% for the nine-month period
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001015820-26-000061 |
| Document: a2026q3prform6-k.htm | 0001015820-26-000061 |
| Document: 0001015820-26-000061-index-headers.html | 0001015820-26-000061 |
| Document: 0001015820-26-000061-index.html | 0001015820-26-000061 |
| Document: 0001015820-26-000061.txt | 0001015820-26-000061 |
| Earnings Context (Synthetic; results releases only) | 0001015820-26-000061 |
Track record
7 reports on QGEN
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +0.99% at T+5 after the Oct 27, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $50.33 to $49.89 Now $49.81 −1.03% ▼ −0.87% −3.47% vs SPY
- Nov 5, 202611d ago 6-K Bearish 6/10 Entry $50.33 to $49.89 Now $49.81 +1.03% ▲ +0.87% +3.47% vs SPY
- Nov 5, 202611d ago 6-K Neutral 5/10 Viewing No price data
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $50.86 to $50.10 Now $49.81 −2.06% ▼ −1.49% −4.78% vs SPY
- Oct 27, 202620d ago SC TO-C Bullish 7/10 Entry $50.33 to $50.83 Now $49.81 −1.03% ▲ +0.99% +1.71% vs SPY
- Oct 23, 202624d ago 6-K Bullish 8/10 Entry $50.39 to $50.22 Now $49.81 −1.15% ▼ −0.34% +0.22% vs SPY
- Oct 22, 202625d ago SC TO-C Bullish 8/10 Entry $50.22 to $50.34 Now $49.81 −0.82% ▲ +0.24% −0.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers